Amicus Therapeutics (FOLD) News Today $6.93 -0.06 (-0.86%) Closing price 08/6/2025 04:00 PM EasternExtended Trading$7.04 +0.11 (+1.52%) As of 08/6/2025 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock FOLD Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives $16.22 Average Target Price from AnalystsAugust 6 at 2:31 AM | americanbankingnews.comAmicus Therapeutics (NASDAQ:FOLD) Trading 9.3% Higher - Here's WhyAugust 5 at 5:56 PM | marketbeat.comAmicus Therapeutics (NASDAQ:FOLD) Rating Increased to Buy at Wall Street ZenAugust 5 at 2:33 AM | americanbankingnews.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Just Released Its Second-Quarter Earnings: Here's What Analysts ThinkAugust 4 at 4:03 AM | finance.yahoo.com187,897 Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Bought by Jefferies Financial Group Inc.August 4 at 3:08 AM | marketbeat.comXTX Topco Ltd Has $871,000 Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)August 4 at 3:08 AM | marketbeat.comAssetmark Inc. Trims Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)August 4 at 3:08 AM | marketbeat.comAmicus Therapeutics Inc (FOLD) Q2 2025 Earnings Call Highlights: Sustained Revenue Growth ...August 3, 2025 | gurufocus.comQ2 2025 Amicus Therapeutics Inc Earnings Call TranscriptAugust 3, 2025 | gurufocus.comAmicus Therapeutics (NASDAQ:FOLD) Upgraded to Buy at Wall Street ZenAugust 3, 2025 | marketbeat.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Consensus Rating of "Moderate Buy" from BrokeragesAugust 3, 2025 | marketbeat.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Q2 2025 Earnings Call TranscriptAugust 1, 2025 | msn.comAmicus (FOLD) Q2 Revenue Jumps 22%August 1, 2025 | fool.comAmicus Therapeutics: Going Beyond $1B Target Revenues Of Lead Products With Licensed DMX-200August 1, 2025 | seekingalpha.comBank of America Securities Remains Bullish on Amicus Therapeutics (FOLD) With a $13 PTAugust 1, 2025 | insidermonkey.comUniversal Beteiligungs und Servicegesellschaft mbH Makes New $1.74 Million Investment in Amicus Therapeutics, Inc. (NASDAQ:FOLD)August 1, 2025 | marketbeat.comY Intercept Hong Kong Ltd Trims Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)August 1, 2025 | marketbeat.comEnvestnet Asset Management Inc. Has $1.52 Million Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)August 1, 2025 | marketbeat.comAmicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate UpdatesJuly 31, 2025 | globenewswire.comVictory Capital Management Inc. Boosts Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)July 29, 2025 | marketbeat.comIn NCLA Amicus Win, Eleventh Circuit Vacates SEC Order Used to Fund Its Illegal Collection of DataJuly 28, 2025 | globenewswire.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Legato Capital Management LLCJuly 26, 2025 | marketbeat.comMorgan Stanley Upgrades Amicus (FOLD) on IP Strength and Pipeline ExpansionJuly 25, 2025 | msn.comDimerix Secures Major Licensing Deal with Amicus TherapeuticsJuly 24, 2025 | tipranks.comAmicus Therapeutics (FOLD) Expected to Announce Earnings on ThursdayJuly 24, 2025 | marketbeat.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by New York State Common Retirement FundJuly 24, 2025 | marketbeat.comAmicus Therapeutics to Announce Second Quarter 2025 Financial Results on July 31, 2025July 21, 2025 | globenewswire.com58,396 Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Purchased by Edgestream Partners L.P.July 20, 2025 | marketbeat.comAmicus gains as Morgan Stanley upgrades on Aurobindo case and Pom-Op switchingJuly 18, 2025 | msn.comAmicus Therapeutics (NASDAQ:FOLD) Shares Gap Up - Here's WhyJuly 17, 2025 | marketbeat.comAmicus Therapeutics (NASDAQ:FOLD) Upgraded at Morgan StanleyJuly 17, 2025 | marketbeat.comAmicus (FOLD) Gets Japan Approval for Pombiliti + OpfoldaJuly 16, 2025 | finance.yahoo.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Acquired by Rice Hall James & Associates LLCJuly 14, 2025 | marketbeat.comStephens Investment Management Group LLC Buys Shares of 612,470 Amicus Therapeutics, Inc. (NASDAQ:FOLD)July 14, 2025 | marketbeat.comQ2 EPS Estimate for Amicus Therapeutics Boosted by AnalystJuly 11, 2025 | marketbeat.comQ1 EPS Estimate for Amicus Therapeutics Lifted by AnalystJuly 10, 2025 | marketbeat.comSHAREHOLDER NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term FOLD Investors to Contact the FirmJuly 10, 2025 | prnewswire.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Given Consensus Rating of "Moderate Buy" by BrokeragesJuly 9, 2025 | marketbeat.comAmicus Therapeutics’ Migalastat Study: A Potential Game-Changer for Fabry Disease TreatmentJuly 3, 2025 | tipranks.comAmicus Therapeutics Advances Pompe Disease Research with New Observational StudyJuly 3, 2025 | tipranks.comAmicus Therapeutics, Inc. (FOLD) - Yahoo FinanceJune 28, 2025 | finance.yahoo.comAmicus Therapeutics stock hits 52-week low at $5.55June 25, 2025 | investing.comJapan approves Amicus Therapeutics' treatment for late-onset Pompe diseaseJune 25, 2025 | investing.comAmicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) in JapanJune 25, 2025 | globenewswire.comAmicus Therapeutics Publishes Positive PROPEL Study Data for Pompe Disease TreatmentJune 24, 2025 | msn.comAmicus Therapeutics (NASDAQ:FOLD) Reaches New 12-Month Low - Time to Sell?June 23, 2025 | marketbeat.comU.S. Supreme Court Decision Cites NCLA's Amicus Brief in Preserving Access to Federal CourtsJune 20, 2025 | globenewswire.comSG Americas Securities LLC Acquires 58,496 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)June 20, 2025 | marketbeat.comAmicus Therapeutics (NASDAQ:FOLD) Hits New 52-Week Low - Time to Sell?June 17, 2025 | marketbeat.comThe Association of American Physicians and Surgeons files an Amicus Brief in the Supreme Court in Support of the Right to Conversion TherapyJune 16, 2025 | globenewswire.com Get Amicus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter. Email Address FOLD Media Mentions By Week FOLD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FOLD News Sentiment▼0.550.42▲Average Medical News Sentiment FOLD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FOLD Articles This Week▼216▲FOLD Articles Average Week Get Amicus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies HALO News IONS News MDGL News RGEN News ALKS News LGND News BCRX News CLDX News DVAX News INVA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FOLD) was last updated on 8/7/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredSell these "safe" blue chips immediatelyInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amicus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amicus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
